Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. [electronic resource]
Producer: 20100706Description: 2982-8 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Cyclophosphamide -- administration & dosage
- Diarrhea -- chemically induced
- Dose-Response Relationship, Drug
- Doxorubicin -- administration & dosage
- Feasibility Studies
- Female
- Filgrastim
- Follow-Up Studies
- Gene Amplification
- Granulocyte Colony-Stimulating Factor -- administration & dosage
- Humans
- Immunoenzyme Techniques
- In Situ Hybridization, Fluorescence
- Lapatinib
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Paclitaxel -- administration & dosage
- Pilot Projects
- Polyethylene Glycols
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- genetics
- Recombinant Proteins
- Survival Rate
- Trastuzumab
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.